Abogen, Inc. Email Format
Biotechnology ResearchMaine, United States2-10 Employees
Abogen, Inc. operates in biotechnology research with a focus on reducing the need for invasive blood draws in research and diagnostic workflows. Founded in 2012, the company asserts that saliva can be used for a range of cell-based applications, including serological and genetic analyses, and has demonstrated this with independent validators. It emphasizes elevating saliva as an alternative to blood rather than replacing it entirely, and it is based in Portland, Maine, operating with a small team. Positioned within the biotechnology research industry, Abogen aims to supply researchers and diagnostic developers with saliva-based approaches to support cell-based tests and analyses. A 2022 report notes the company’s involvement in developing mRNA-based vaccines for Covid-19 and dengue, along with provisional collaboration discussions with CanSino and Walvax to pursue additional vaccine programs.